StreetInsider.com News Articles

Aardvark Therapeutics Inc (AARD) PT Lowered to $7 at B.Riley

Fri, 15 May 2026 08:40:59 -0400

B.Riley analyst William Wood lowered the price target on Aardvark Therapeutics Inc (NASDAQ: AARD) to $7.00 (from $8.00) while maintaining a Buy rating.

BTIG Downgrades Aardvark Therapeutics Inc (AARD) to Neutral

Fri, 15 May 2026 07:53:33 -0400

BTIG analyst Jeet Mukherjee downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Buy to Neutral.

The analyst comments "The FDA has placed a full clinical hold on ARD-101, escalating from AARD's voluntary pause announced in Feb and formally halting the ph 3 HERO trial and its OLE. We connected with mgmt following the announcement, who noted that the 68 pts dosed in HERO and 19 in the OLE are insufficient to support regulatory approval, and that a new trial will be required. While mgmt noted their FDA interactions have been constructive regarding steps needed to understand the QRS signal and potential future

BTIG Downgrades Aardvark Therapeutics Inc (AARD) to Neutral

Fri, 15 May 2026 07:53:33 -0400

BTIG analyst Jeet Mukherjee downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Buy to Neutral.

Morgan Stanley Downgrades Aardvark Therapeutics Inc (AARD) to Underweight

Fri, 15 May 2026 03:35:24 -0400

Morgan Stanley analyst Michael E Ulz downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Equalweight to Underweight with a price target of $3.00 (from $7.00).

The analyst comments: “After the close, Aardvark announced (PR here) the FDA placed ARD-101 on full clinical hold related to the safety findings, which prompted the company to voluntarily pause the ongoing Ph3 HERO study in Prader-Willi syndrome (PWS; notes here and here), earlier this year. As a reminder, in a healthy volunteer (HV) study Aardvark observed reversible QRS prolongation in patients treated at double the dose used in the HERO study (1,600 mg BID w/o dose

Morgan Stanley Downgrades Aardvark Therapeutics Inc (AARD) to Underweight

Fri, 15 May 2026 03:35:24 -0400

Morgan Stanley analyst Michael E Ulz downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Equalweight to Underweight with a price target of $3.00 (from $7.00).

Form 8-K Aardvark Therapeutics, For: May 14

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495191.html

Form 8-K Aardvark Therapeutics, For: May 14

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495191.html

FDA places clinical hold on Aardvark Therapeutics ARD-101 drug trials

Thu, 14 May 2026 16:01:46 -0400

The U.S. Food and Drug Administration has placed a full clinical hold on Aardvark Therapeutics Inc.'s (NASDAQ: AARD) investigational new drug application for ARD-101, affecting all ongoing clinical studies under the application. The hold applies to the company's Phase 3 HERO trial evaluating ARD-101 for treating hyperphagia in patients with Prader-Willi Syndrome and the Phase 3 open-label extension trial.

The clinical hold follows Aardvark's previously announced voluntary pause of the trials. The San Diego-based biopharmaceutical company said it remains in discussions with the FDA to resolve the hold and determine next steps for the ARD-101 program.

"We are continuing to work collaboratively

FDA places clinical hold on Aardvark Therapeutics ARD-101 drug trials

Thu, 14 May 2026 16:01:46 -0400

"We are continuing to work collaboratively

FDA places clinical hold on Aardvark Therapeutics ARD-101 drug trials

Thu, 14 May 2026 16:01:46 -0400

"We are continuing to work collaboratively

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

Thu, 14 May 2026 16:01:00 -0400

SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company’s previously announced voluntary pause. The clinical hold applies to all ongoing clinical studies under the IND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the treatment of hyperphagia in

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

Thu, 14 May 2026 16:01:00 -0400

Form 10-Q Aardvark Therapeutics, For: Mar 31

Thu, 07 May 2026 09:33:00 -0400

si-local-file:///var/storage/secattach/20260507/26450136.html

Form 10-Q Aardvark Therapeutics, For: Mar 31

Thu, 07 May 2026 09:33:00 -0400

si-local-file:///var/storage/secattach/20260507/26450136.html

Form 8-K Aardvark Therapeutics, For: May 07

Thu, 07 May 2026 09:28:00 -0400

si-local-file:///var/storage/secattach/20260507/26450080.html

Form 8-K Aardvark Therapeutics, For: May 07

Thu, 07 May 2026 09:28:00 -0400

si-local-file:///var/storage/secattach/20260507/26450080.html

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Thu, 07 May 2026 08:00:00 -0400

ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026